Solara Active Pharma Sciences Limited

NSEI:SOLARA 株式レポート

時価総額:₹26.2b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Solara Active Pharma Sciences 過去の業績

過去 基準チェック /06

Solara Active Pharma Sciencesの収益は年間平均-61.4%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間17% 0.5%割合で 減少しています。

主要情報

-61.4%

収益成長率

-68.7%

EPS成長率

Pharmaceuticals 業界の成長17.5%
収益成長率-0.5%
株主資本利益率-60.5%
ネット・マージン-44.0%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

Jun 05
Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

May 11
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Apr 19
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Feb 23
Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Jan 04
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

May 12
Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Nov 08
Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Sep 30
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Aug 03
Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Jun 19
Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Dec 21
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Is Interesting

Oct 28
With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Is Interesting

収支内訳

Solara Active Pharma Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NSEI:SOLARA 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
31 Mar 2412,889-5,6742,4390
31 Dec 2314,069-3,0772,5030
30 Sep 2315,529-3252,4610
30 Jun 2314,661-2532,3590
31 Mar 2314,438-2222,3080
31 Dec 2214,240-2412,1500
30 Sep 2211,296-1,6442,2210
30 Jun 2211,928-1,2472,3190
31 Mar 2212,683-5812,3920
31 Dec 2113,517-342,5290
30 Sep 2116,7812,0232,4720
30 Jun 2116,7402,2932,3930
31 Mar 2116,1692,2142,3270
31 Dec 2014,6941,8262,2970
30 Sep 2013,8641,5812,2120
30 Jun 2013,4001,3042,1390
31 Mar 2013,2181,1462,0800
31 Dec 1914,1031,2312,0590
30 Sep 1914,2281,0392,0320
30 Jun 1914,1408451,9860
31 Mar 1913,8676141,9270
31 Mar 185,210607100

質の高い収益: SOLARAは現在利益が出ていません。

利益率の向上: SOLARAは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: SOLARAは利益が出ておらず、過去 5 年間で損失は年間61.4%の割合で増加しています。

成長の加速: SOLARAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SOLARAは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 18.4% ) と比較することは困難です。


株主資本利益率

高いROE: SOLARAは現在利益が出ていないため、自己資本利益率 ( -60.54% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘